Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Income from Continuing Operations of 45340000.0 for Q1 2026, up 75.44% sequentially from 184601000.0 in Q4 2025, and down 2.01% YoY from 46269618.86 in Q1 2025.
Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Income from Continuing Operations for 5 years, with the latest figure at 45340000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 2.01% year-over-year to 45340000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 317818000.0 (down 12.93% YoY) and the FY2025 annual result came in at 316925000.0, down 16.37% from the prior year.
- Income from Continuing Operations rose to 45340000.0 in Q1 2026 per MLYS's latest filing, from 184601000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6479000.0 in Q2 2022 and troughed at 184601000.0 in Q4 2025.
- A 5-year average of 44221941.18 and a median of 35362000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 360.99% in 2024, then jumped 31.57% in 2025.
- Over 5 years, Income from Continuing Operations stood at 10191000.0 in 2022, then tumbled by 180.33% to 28568000.0 in 2023, then tumbled by 360.99% to 131696000.0 in 2024, then tumbled by 40.17% to 184601000.0 in 2025, then surged by 75.44% to 45340000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 45340000.0, 184601000.0, and 41131000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | -248.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -248.42 Mn |
| Mar 31, 2026 | -45.34 Mn |
| Dec 31, 2025 | -184.60 Mn |
| Sep 30, 2025 | -41.13 Mn |
| Jun 30, 2025 | -46.75 Mn |
| Mar 31, 2025 | -44.45 Mn |
| Dec 31, 2024 | -131.70 Mn |
| Sep 30, 2024 | -60.11 Mn |
| Jun 30, 2024 | -45.17 Mn |
| Mar 31, 2024 | -35.36 Mn |
| Dec 31, 2023 | -28.57 Mn |
| Sep 30, 2023 | -26.27 Mn |
| Jun 30, 2023 | -15.74 Mn |
| Mar 31, 2023 | -14.94 Mn |
| Dec 31, 2022 | -10.19 Mn |
| Sep 30, 2022 | -7.42 Mn |
| Jun 30, 2022 | -6.48 Mn |
| Mar 31, 2022 | -7.57 Mn |